Form 4: Elanco EVP Disposes Shares for Tax Obligations

Elanco Animal Health's Executive Vice President, Jose Manuel Correia de Simas, reported a disposition of 3,371 common shares for tax liability purposes.

Summary

• Jose Manuel Correia de Simas, Executive Vice President, US Farm Animal Business at Elanco Animal Health Inc. (ELAN), reported a transaction.
• On March 3, 2026, 3,371 shares of common stock were disposed of.
• The transaction was coded 'F', indicating the shares were withheld to cover tax liabilities.
• The price per share for the disposition was $24.88.
• Following this transaction, Mr. Correia de Simas beneficially owns 101,017 shares of Elanco common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The disposition of shares is for tax purposes and was pre-planned, indicating no discretionary selling based on new information, thus having no material impact on company sentiment.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1(c) plan, indicating a planned and routine event rather than a discretionary sale.

Negatives

• A reduction in direct beneficial ownership by an executive, even for tax purposes, slightly decreases insider alignment.

Risks

• No specific risks to the company are directly indicated by this routine insider transaction.

Future Outlook

Not applicable as this filing reports a past insider transaction and does not contain forward-looking statements or guidance.

Management Comments

• Jose Manuel Correia de Simas holds the title of Executive Vice President, US Farm Animal Business.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as dispositions for tax purposes, are common across all industries and are typically not indicative of significant shifts in company performance or executive sentiment. This filing is a standard regulatory disclosure.

Comparison to Industry Standards

• Not applicable as this filing details a routine insider transaction for tax purposes, not company performance metrics that can be benchmarked against industry peers or global standards.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• No related party dealings are disclosed in this filing.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a routine, pre-planned tax-related disposition by an executive, not a discretionary sale.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Next Steps

• No specific future actions or milestones are mentioned in this filing.

Key Dates

Keywords

Elanco Animal Health, ELAN, Insider Transaction, Form 4, Jose Manuel Correia de Simas, Stock Disposition, Tax Withholding, Rule 10b5-1